A carregar...
Excellent Response to Anti-PD-1 Therapy in a Patient with Hepatocellular Carcinoma Intolerant to Sorafenib
BACKGROUND: Hepatocellular carcinoma (HCC) represents the most common primary carcinoma of the liver. Most patients present with advanced or metastatic HCC at diagnosis and face a very limited prognosis. Systemic treatment with the tyrosine-kinase inhibitors sorafenib or lenvatinib is considered as...
Na minha lista:
| Publicado no: | Visc Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
S. Karger AG
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6597928/ https://ncbi.nlm.nih.gov/pubmed/31312649 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000497465 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|